SCHEMBL17849753

SCHEMBL17849753

S=c1cc(-c2ccncc2)ss1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 8/20 0.59
HDAC3 O15379 7/20 0.59
HDAC4 P56524 7/20 0.59
HDAC1 Q13547 7/20 0.59
HDAC7 Q8WUI4 7/20 0.59
HDAC2 Q92769 7/20 0.59
HDAC10 Q969S8 7/20 0.59
HDAC11 Q96DB2 7/20 0.59
HDAC6 Q9UBN7 7/20 0.59
HDAC9 Q9UKV0 7/20 0.59
HDAC5 Q9UQL6 7/20 0.59
MEN1 O00255 1/20 0.53
PGR P06401 1/20 0.53
ADRB2 P07550 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
MAOA P21397 1/20 0.53
TBXA2R P21731 1/20 0.53
SLC6A2 P23975 1/20 0.53
NPY1R P25929 1/20 0.53
ADORA2A P29274 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17849758 0.75 HDAC3 (0.46) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL28820748 0.74 HDAC3 (0.64) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL9534281 0.74 HDAC3 (0.64) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL2462288 0.74 HDAC3 (0.59) HDAC8HDAC3HDAC4HDAC1HDAC7
Anetholtrithion SCHEMBL225654 0.69 MEN1 (1.00) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL19002178 0.69 HDAC3 (0.58) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL15928850 0.69 HDAC3 (0.58) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL19002183 0.69 HDAC6 (0.58) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL11040858 0.68 HDAC3 (0.52) HDAC8HDAC3HDAC4HDAC1HDAC7
SCHEMBL12601934 0.68 HDAC3 (0.56) HDAC8HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9370504-B2 Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α SNU R&DB FOUNDATION (KR) 2016-06-21 US disclosed